I think POZN just got dragged down with the rest of the market, definitely oversold here by a wide margin. But I really don't expect it to have "the" big run until more PA325 news comes out, that is the *real* jewel in their crown. Treximet and Vivimo will just pay the bills and add to their cash on hand until the "safer aspirin" is approved. I considered buying some more today, but I already have quite a bit of money invested in it, don't want to go overboard.
I just did a whole bunch of trades in my IRA to take advantage of the fire sale prices almost everything is selling at right now. I closed my RNE position (Morgan Stanley Eastern Europe) at a 30% profit (was up as high as 63% since I bought it in Nov 08), I finally decided I have too much exposure to the European mess and that CEF was the worst rated of the ones I own, although it had been very good to me.
I used the proceeds to increase my positions in SFL (just raised their div from $0.30 to $0.33, ex div is 5/28), HYB, and PHT, all at prices ~ equal to my original buys, and of course more of our dear XCHO. I bought 20,400 shrs at $0.22, more than doubling my IRA share count, and lowered my basis from $0.327 to $0.264. Now I'll just sit back and wait for things to recover and XCHO to blow the roof off next quarter!
Market Data 
Markets 
AI
